Advertisement

Topics

CryoLife Inc. Company Profile

04:19 EDT 25th June 2018 | BioPortfolio

Founded in 1984, CryoLife was the first company to commercially develop the ultra-low temperature preservation of viable human heart valves for transplant. Since then, we have been engaged in an exciting transfer of technology which has led to the highly successful preservation of human saphenous and femoral veins as well as orthopaedic tissues such as tendons, menisci, and osteo-articular cartilage grafts. Today, the company holds thirteen exclusive cryopreservation patents, including the CryoSafe® triple pouch packaging system (patent #no. 5,031,762) designed to withstand ultra-cold temperatures and allow for aseptic introduction of the allograft into the sterile field.
Our laboratories and research facilities, located in suburban Atlanta, Georgia, have been designed to maximize the quality of our tissues and services. Tissue processing is conducted in a class 100 clean room environment by CryoLife technicians trained in microsurgical techniques. An in-house microbiology department performs extensive testing on each type of tissue for bacterial and fungal contamination. All donors are screened according to FDA regulations.

Our quality management system has been awarded the coveted ISO certification, an internationally recognized sign of quality assurance excellence. As a company, we are wholly committed to advancing the evolution of tissue preservation and engineering technology.

Location

1655 Roberts Blvd., NW
Kennesaw
Georgia
30144
United States of America

Contact

Phone: 770.419.3355
Fax: 770.426.0031
Email: info@cryolife.com


News Articles [7 Associated News Articles listed on BioPortfolio]

CryoLife's (CRY) CEO Pat Mackin on Q1 2018 Results - Earnings Call Transcript

CryoLife's (CRY) CEO Pat Mackin on Q4 2017 Results - Earnings Call Transcript

Global Medical Adhesives and Sealants Market Survey and Trend Research 2018 [Report Updated: 27012018] Prices from USD $2600

SummaryThis report describes the development of the industry by upstream downstream, industry overall and development, key companies, as well as type segment market application and so on, and makes ...

Global and Europe Tissue Engineering Market Status and Future Forecast 20132023 [Report Updated: 11012018] Prices from USD $3500

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

20152023 World Medical Adhesives and Sealants Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 03022018] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and en...

Global Medical Adhesives and Sealants Market Research Report 2018 [Report Updated: 05012018] Prices from USD $3500

SummaryMarket Segment as follows:By Region AsiaPacific North America Europe South America Middle East AfricaBy Type Acrylic Silicone Rubber OthersBy Application Acrylic ...

20152023 World Biomaterial Implants Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 14022018] Prices from USD $2800

SummaryxxxThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and...

Drugs and Medications [0 Results]

None

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Pseudoaneurysm rupture after acute Type A dissection repair: possible reaction to BioGlue.

A 45-year-old man with acute Type A aortic dissection underwent the ascending aorta replacement with BioGlue (CryoLife Europa, Guildford, Surrey, UK) for anastomotic reinforcement. Postoperatively, he...

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

CryoLife, Inc.

CryoLife Inc.

Founded in 1984, CryoLife was the first company to commercially develop the ultra-low temperature preservation of viable human heart valves for transplant. Since then, we have been engaged in an excit...

More Information about "CryoLife Inc." on BioPortfolio

We have published hundreds of CryoLife Inc. news stories on BioPortfolio along with dozens of CryoLife Inc. Clinical Trials and PubMed Articles about CryoLife Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CryoLife Inc. Companies in our database. You can also find out about relevant CryoLife Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Transplantation
Organ transplantation is the moving of an organ from one body to another or from a donor site to another location on the patient's own body, for the purpose of replacing the recipient's damaged or absent organ. The emerging field of regenerative ...


Corporate Database Quicklinks



Searches Linking to this Company Record